NLAB Silica Technology

In the Drug Delivery business area, Nanologica develops nanoporous silica, NLAB SilicaTM, for the improved delivery of Active Pharmaceutical Ingredients (APIs) in oral dosage form. Up to 90% of oral medicines in development today suffer from low oral solubility. This can compromise the efficacy and safety of new drug compounds leading to poor patient response and prohibit further drug development. Nanologica uses its extensive knowledge of interactions between APIs and the materials in its broad NLAB SilicaTM portfolio in order to develop new pharmaceutical formulations with dramatic improvement in solubility, stability and handling.